Main Article Content
Numerous patients with coronavirus infection 2019 (COVID-19) have comorbidities identified with the metabolic syndrome (MS) during their illness course. Patients with compromised immune levels are under considerable risk of COVID-19 infection.
We systematically searched the PubMed and Google Scholar databases until July 22nd, 2020, and got to the accessible information on the relationship between metabolic syndrome, diabetes, Tuberculosis (TB), and COVID-19.
Most of the investigations assumed that 5-30% of TB patients have diabetes mellitus (DM). Diabetes is a significant cause of Lower respiratory tract infections (LRTI), including TB. MS is rising in developed and developing countries in both males and females. It leads to a reduction in pulmonary function and more chances of death. Difficulty in breathing at rest conditions and exacerbations are the most common symptoms in Metabolic syndrome, TB, and COVID-19 infection.
Diabetes, MS, and TB are the significant risk factors influencing the development and prognosis of COVID-19. Recommendations for clinical practice, which include the performance of tridirectionally screening [TB, DM, COVID-19]. Monitoring of blood glucose levels in patients suffering from Tuberculosis and COVID-19 infection. In case of the presence of diabetes in patients suffering from those infections, management of the glycemic condition has to be done to stabilize the patient's condition.